𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

✍ Scribed by Duvic, Madeleine; Dummer, Reinhard; Becker, Jürgen C.; Poulalhon, Nicolas; Ortiz Romero, Pablo; Grazia Bernengo, Maria; Lebbé, Celeste; Assaf, Chalid; Squier, Margaret; Williams, Denise; Marshood, Miriam; Tai, Feng; Prince, H. Miles

Book ID
122469730
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
283 KB
Volume
49
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a Phase II trial of oral bexa
Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma
✍ David J. Straus; Madeleine Duvic; Timothy Kuzel; Steven Horwitz; Marie-France De 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## Abstract ## BACKGROUND. Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T‐cell lymphoma (CTCL). Interferon alfa has also been used for many years as an effective treatment for this disease. The results in recent case reports of the combi

RESEARCH REPORT Bexarotene capsules and
RESEARCH REPORT Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: Results of the Australian patients treated on phase II trials
✍ H Miles Prince; Christopher McCormack; Gail Ryan; Christopher Baker; Harvey Rots 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## SUMMARY Bexarotene (Targretin^®^, LGD1069) is a novel synthetic retinoid analogue that binds selectively to retinoid X receptors. We describe eight previously treated patients who entered phase II international multicentre studies examining the role of bexarotene in cutaneous T‐cell lymphoma. Pa

Phase II trial of interferon-α-2a plus p
Phase II trial of interferon-α-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma
✍ Vanna Chiarion-Sileni; Antonio Bononi; Cleto Veller Fornasa; Mariella Soraru; Ma 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Purpose: To evaluate the efficacy and side effects of psolaren with ultraviolet light a (puva) and interferon-alpha-2a (ifn-alpha-2a) in patients with mycosis fungoides (mf) and sézary syndrome (ss). ## Patients and methods: From may 1993 to january 1999, 63 symptomatic patients with all stage